Cargando…

Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia

Detalles Bibliográficos
Autores principales:	Garrido, C, Rallón, N, Zahonero, N, de la O López, M, Soriano, V, de Mendoza, C, Benito, JM
Formato:	Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999382/ http://dx.doi.org/10.1186/1758-2652-13-S3-O12

Ejemplares similares

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals
por: Cevik, Muge, et al.
Publicado: (2012)

What happens to cardiovascular system behind the undetectable level of HIV viremia?
por: d’Ettorre, Gabriella, et al.
Publicado: (2016)

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
por: Ashby, J, et al.
Publicado: (2010)

Low-level residual viremia and risk of virological failure
por: Cologni, G, et al.
Publicado: (2010)

Immunodominant Anti-Gag SLYNTVATL Responses in HIV-patients With More Than Five Years of HAART-induced Undetectable Plasma Viremia
por: Remenar, Anica, et al.
Publicado: (2005)

Tuberculosis but not Immune Reconstitution Inflammatory Syndrome (IRIS) prevents early and late NK cell degranulation reconstitution in HIV/TB co-infected patients
por: Pean, Polidy, et al.
Publicado: (2011)

HIV low-level persistent viremia under new antiretroviral regimens: what we have learned up to this point?
por: Gheorghiță, Valeriu, et al.
Publicado: (2014)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Liver fibrosis is strongly associated with an enhanced level of immunosuppressive tryptophan catabolism independently of HCV viremia in ART-treated HIV/HCV co-infected patients
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia
por: Višković, Klaudija, et al.
Publicado: (2018)

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
por: Fernández-Montero, JV, et al.
Publicado: (2010)

Preservation of a subset of SIV-specific central memory CD4+ T cells correlates with control of viremia in SIVmac251 infected macaques
por: Felber, Barbara K, et al.
Publicado: (2006)

CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut
por: Yukl, S, et al.
Publicado: (2010)

Family Based Treatment for anorexia nervosa and reconstituted families
por: Litster, Richard, et al.
Publicado: (2014)

Retracing the evolutionary emergence of thymopoiesis
por: Swann, Jeremy B., et al.
Publicado: (2020)

Limited Evolution of Inferred HIV-1 Tropism while Viremia Is Undetectable during Standard HAART Therapy
por: Lee, Guinevere Q., et al.
Publicado: (2014)

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
por: Tossonian, HK, et al.
Publicado: (2010)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?
por: Martín-Carbonero, L, et al.
Publicado: (2010)

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2010)

Minimally invasive and surface electroporation delivery of DNA vaccines for the induction of robust humoral immune responses against HIV antigens
por: Sardesai, NY, et al.
Publicado: (2012)

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2011)

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation
por: da Rocha, Luis Klaus A., et al.
Publicado: (2018)

Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection
por: Santos, Carla Regina Gomes Rodrigues, et al.
Publicado: (2022)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
por: Doroana, M, et al.
Publicado: (2010)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

76. Effects of the “Undetectable = Untransmittable” (“U=U”) Educational Campaign on Treatment Outcomes and Perceptions among People Living with HIV in North American Countries
por: Spinelli, Frank, et al.
Publicado: (2021)

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission
por: Lingappa, JR, et al.
Publicado: (2009)

Tregs combined with mature donor T cells hasten immune reconstitution without triggering GvHD in HLA haploidentical transplantation
por: Di Ianni, Mauro, et al.
Publicado: (2011)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine
por: Funderburg, Nicholas T., et al.
Publicado: (2013)

Thymopoiesis and regulatory T cells in healthy children and adolescents
por: Arismendi, Maria Izabel, et al.
Publicado: (2012)

Kaposi's sarcoma-associated immune reconstitution inflammatory syndrome (KS-IRIS) in Africa: initial findings from a prospective evaluation
por: Martin, JN, et al.
Publicado: (2009)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
por: Pasternak, Alexander O., et al.
Publicado: (2009)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing
por: Vandekerckhove, LPR, et al.
Publicado: (2010)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_sk5r03k260eofah1b2tp90lg91